

---

December 10, 2021

**BSE Limited**

**Code: 532321**

1<sup>st</sup> Floor,  
P J Towers,  
Dalal Street,  
Mumbai-400001

**National Stock Exchange of India Limited**

**Code: Cadilahc**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Re.:** Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated December 10, 2021 titled "**Zydus Cadila receives tentative approval from USFDA for Cariprazine Capsules**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

## Zydus Cadila receives tentative approval from USFDA for Cariprazine Capsules

Ahmedabad, India, 10 December, 2021

Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Cariprazine Capsules in the strengths of 1.5 mg, 3 mg and 4.5 mg, and 6 mg (US RLD: VRAYLAR®). Cariprazine is an atypical antipsychotic. Zydus' Cariprazine Capsules are indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar disorder. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

### About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

\*\*\*